“We are excited and fortunate to have these four highly accomplished professionals join our team,” commented Marker Therapeutics’ President & CEO Peter L. Hoang.
The company is the product of a merger between TapImmune and Marker Therapeutics that completed on Oct 17th, 2018 and on Thursday, October 18th begins trading under the ticker (NASDAQ: MRKR), retiring TapImmune’s ticker (TPIV).
Marker Therapeutics, Inc. President and CEO, Peter L. Hoang, will be participating in conferences next week.
“The closing of this merger marks a significant milestone, since the combined company is well-positioned to become a leader in cancer immunotherapy, with potentially transformative therapies,” said Peter Hoang, CEO of Marker Therapeutics, Inc.
Learn more about Marker Therapeutics, Inc. by going to markertherapeutics.com
The Department of Defense awarded more than $11 million for this Jacksonville study.
Peter L. Hoang, President and CEO of TapImmune, stated, “I am delighted that the U.S. Department of Defense has again chosen to support our technology and therapeutic platform with another funding commitment.
Peter L. Hoang will be presenting at the 2018 Cantor Global Healthcare Conference and the Sachs Associates 18th Annual Biotech in Europe Forum. Webcast will be available for both events.